Xeris Biopharma Holdings (XERS) Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $32.3 million for Q1 2026.

• Quarterly Accumulated Expenses rose 61.03% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (up 61.03% YoY) and the FY2025 annual result came in at $33.2 million, up 19.62% from the prior year.
• Accumulated Expenses was $32.3 million for Q1 2026 at Xeris Biopharma Holdings, down from $33.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $37.7 million in Q3 2022 and bottomed at $19.1 million in Q3 2023.
• A 5-year average of $27.4 million and a median of $25.0 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 64.25% — and 2023, when it tumbled 49.42%.
• Xeris Biopharma Holdings' Accumulated Expenses stood at $36.8 million in 2022, then sank by 36.09% to $23.5 million in 2023, then advanced by 17.89% to $27.7 million in 2024, then gained by 19.62% to $33.2 million in 2025, then fell by 2.62% to $32.3 million in 2026.
• Business Quant data shows XERS's Accumulated Expenses at $32.3 million in Q1 2026, $33.2 million in Q4 2025, and $30.4 million in Q3 2025.